UroGen Pharma Ltd. — Director's Dealing 2021

Jun 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2021-06-05

Reporting Person: Henderson Molly (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-05	Stock Option (right to buy)	$17.98	A	15000	Acquired	2031-05-31	Common Stock (15000)	Direct

Footnotes

F1: 1/3 of the shares underlying the stock options will vest on each of June 1, 2022, June 1, 2023 and June 1, 2024.